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Bromopyridazinedione-mediated bioconjugation to a cysteine
containing protein and a disulﬁde containing peptide is described.
The conjugates are cleavable in an excess of thiol, including
cytoplasmically-relevant concentrations of glutathione, and show
a high level of hydrolytic stability. The constructs have the
potential for four points of chemical attachment.
The published sequence of the human genome revealed
encoding for only one tenth of the total proteome. The role
of protein post-translational modiﬁcation has therefore
become of intense interest in understanding complex, physio-
logical processes. Combining synthetic organic chemistry with
molecular biology has enabled the construction of a range of
proteins and peptides as probes to aid in this venture. This
has allowed the introduction of synthetic post-translational
modiﬁcations1–3 and a variety of ﬂuorescent,4–6 radiolabelled7
and aﬃnity tags8–10 into a variety of protein and peptide
structures. The selective modiﬁcation of cysteine remains a
popular method for achieving protein modiﬁcation. This is
due to its low natural abundance, high nucleophilicity and
the ease with which cysteine can be introduced at desired
locations in protein sequences using modern molecular bio-
logy methods.11–12
In our laboratory, we have recently become interested in the
construction of protein bioconjugates that are cleavable in a
reducing environment. We believe that such an approach
could deliver reversible aﬃnity or ﬂuorescent labels, or con-
structs cleavable under cytoplasmic conditions with potential
as prodrugs. Maleimides are known to react rapidly and
selectively, but irreversibly, with thiols. However, we have
recently demonstrated an approach to reversible cysteine
bioconjugation using bromomaleimides, where retention of
the maleimide double bond allows cleavage of the constructs
via conjugate addition reaction.13 Using bromomaleimides we
have been able to demonstrate the modular construction of
complex bioconjugates, without requirement for reagent pre-
activation, that have three points of chemical attachment.
Following on from this success, we are interested to determine
whether the ability to construct reversible constructs is
something that is restricted to maleimides or whether other
cyclic or acyclic haloeneamide systems will aﬀord alternative
opportunities.
We report herein the use of both monobromo- and dibromo-
1,2-dihydro-pyridazine-3,6-diones (MBPDs 1 and DBPDs 2)
(Fig. 1) to assemble cleavable bioconjugates. The bioconjugates
generated demonstrate exceptional hydrolytic stability with
the potential for four points of chemical attachment. We
have previously shown that hydrolytic stability is crucial in
preserving the thiol-cleavable property of bromomaleimide-
linked bioconjugates.13d
Our initial studies focused on the functionalisation of a
single cysteine mutant (L111C) of the SH2 domain of the Grb2
adapter protein 3,13a a protein that does not otherwise contain
any cysteine residues, with pyridazinedione (PD) 4 (100 mol
eq., 37 1C, 16 h). No reaction was seen to occur (Scheme 1).
The absence of reactivity observed with PD-4 may be ratio-
nalised by the acidic nature of its hydrazide protons. At pH 8,
PD-4 will predominantly exist in an unreactive, anionic
form.14 However, treatment of protein 3 with PD-5 (100 mol
eq., 37 1C, 16 h) yielded quantitative conversion to the desired
conjugate 6 (Scheme 1). As this protein sequence contains
eight lysine residues, the reaction with PD-5 demonstrates
remarkable selectivity for cysteine as was evidenced following
an absence of reaction with Ellman’s reagent. To our knowl-
edge, this is the ﬁrst reported example of a pyridazinedione
being used to modify cysteine.
Encouraged by the successful functionalisation of protein 3
with PD-5, we sought to synthesise and evaluate MBPD-7 and
DBPD-8 as reagents for the reversible bioconjugation of
proteins. Synthesis of both 7 and 8 was achieved in high yield
by the initial condensation of maleic anhydride with diethyl-
hydrazine followed by sequential dibromination/elimination
steps (Scheme 2).
Fig. 1 (Di)bromo-1,2-dihydro-pyridazine-3,6-diones.
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Treatment of protein 3 with MBPD-7 (100 mol eq., 37 1C,
1 h) gave quantitative conversion to the desired adduct 9
most likely via a conjugate addition–elimination mechanism.
Retention of the double bond in 9 (cf. adduct 6) created the
possibility of reversing this modiﬁcation in an excess of
thiol. Dialysis of the crude product mixture allowed removal
of excess MBPD-7. Subsequent treatment of the MBPD-
modiﬁed protein with 2-mercaptoethanol (BME) (100 mol
eq., 20 1C, 1 h) gave quantitative conversion back to protein
3, highlighting the potential of bromopyridazinediones
to mediate reversible protein bioconjugation (Scheme 3).
Conjugate 9 displayed excellent hydrolytic stability at physio-
logical temperature and was completely stable at 37 1C for 5 h.
Addition of DBPD-8 (100 mol eq., 37 1C, 1 h) to protein 3
gave adduct 10. Gratifyingly, addition of thioglucose, sodium
salt (10 mol eq., 24 1C, 1 h) as a second thiol nucleophile,
following dialysis of the crude product mixture, gave bio-
conjugate 11 in high conversion. Treatment of bioconjugate
11 with an excess of BME (100 mol eq., 24 1C, 1 h) gave
disassembly of the conjugate, yielding protein 3. (Scheme 3).
Bioconjugate 11 was also seen to demonstrate excellent hydro-
lytic stability at 37 1C for 5 h.
The observed cleavage of protein/pyridazine constructs in
an excess of thiol suggests that this scaﬀold could potentially
form the core of novel prodrug systems. Such prodrugs could
be designed and optimised to cleave in the cytoplasm of
mammalian cells, which contain a relatively high concentra-
tion of the thiol glutathione (GSH) (1–10 mM). As a proof
of principle, we subjected bioconjugate 11 to an excess of GSH
(1 mM) at physiological pH. Bioconjugate 11 was seen to
quantitatively disassemble, yielding protein 3 under these
conditions (Scheme 4).
In addition to the functionalisation of free cysteine in
proteins, we are also interested in the labeling of disulﬁde
bonds. We have recently shown the potential of bridging
disulﬁde bonds with dibromomaleimide bridging agents,
yielding conjugates that retain biological activity.13a,c We
now wish to demonstrate how dibromopyridazinedione 8
can be used to successfully bridge the disulﬁde bond of peptide
hormone somatostatin in a reversible manner. Thus treat-
ment of somatostatin 12 (pH 6.2) with tris-(2-carboxyethyl)-
phosphine (TCEP) (1.1 mol eq.) followed by DBPD-8 (5 mol
eq., 20 1C, 2 h) gave complete conversion to the desired
bridged somatostatin 13. Subsequent treatment of 13 with
BME (100 mol eq., 20 1C, 72 h) gave reversion to reduced
somatostatin 14 (containing 1015% of somatostatin/BME
adduct) (Scheme 5).
In conclusion, we have shown how both mono- and
di-bromopyridazinediones can be used to mediate reversible
protein and peptide bioconjugation. More speciﬁcally, we
have demonstrated the selective modiﬁcation of a free cysteine
residue in a protein and also that dibromopyridazinedione 8
can be used to successfully bridge the disulﬁde bond of the
peptide hormone somatostatin. These modiﬁcations have been
shown to be reversible in an excess of thiol such as BME, and
Scheme 1 Modiﬁcation of Grb2-SH2 domain (L111C) 3 with 1,2-
dihydro-pyridazine-3,6-diones.
Scheme 2 Synthesis of (di)bromo-1,2-dihydro-pyridazine-3,6-diones.
Scheme 3 Reversible modiﬁcation of Grb2-SH2 domain (L111C) 3
with (di)bromo-1,2-dihydro-pyridazine-3,6-diones.
Scheme 4 Cleavage of Grb2-SH2 domain (L111C)/thioglucose
conjugate 11 in a cytoplasmically-relevant concentration of GSH.
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the protein modiﬁcation was shown to cleave in a physio-
logically relevant concentration of GSH.
We envisage numerous potential applications for this
methodology that will exploit the thiol-cleavable and hydro-
lytically stable nature of this modiﬁcation. These include the
synthetic PTM of proteins; cleavable aﬃnity tags for protein
puriﬁcation, enrichment and immobilisation; cleavable ﬂuoro-
phores, radiolabels and quantum dots for imaging; cleavable
PEGylation for protein stabilisation; prodrugs designed to
cleave in the cytoplasmic environment of cells. In addition,
the potential for four points of attachment creates the possi-
bility of the multi-labelling of protein conjugates via a single
cysteine or disulﬁde modiﬁcation. Application and further
evaluation of this methodology will be reported in due course.
The authors are grateful to RCUK, EPSRC, BBSRC,
UCL and the Wellcome Trust and UCLB for support of our
programme.
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